I have been through one internal appeal already and would like to do the next one properly.
I can parse the result. I am less sure what it licenses me to conclude.
I have deliberately not looked at anyone else’s interpretation yet.
Which parts of this are informative and which are decoration?
Section 503A is an exemption, not an approval, and it is conditional on four things. A patient-specific prescription; a licensed pharmacist or physician doing the compounding in a licensed facility; bulk substances that either have a USP monograph, appear on the FDA's 503A bulks list, or are components of an approved drug, each with a certificate of analysis from a registered supplier; and the preparation must not be essentially a copy of a commercially available drug. That last condition is the one that moves: it turns on the shortage list, and what was lawful under 503A while a product was in shortage stops being lawful when the shortage is resolved. None of the four requires the finished preparation to be tested, which is the gap that independent assay fills.
Answer first: the two categories differ in whether a prescription for a named patient is required and in which quality standards apply, and that difference decides everything downstream.
Beyond-use dating differs by category and by the preparation environment, and an unusually long date on a compounded sterile preparation is worth asking about.
The relevant detail is that registration status is published and searchable. Checking it takes a minute and is the single most useful verification available in this whole area.
The two-tier structure separating patient-specific compounding from outsourcing facilities is established in federal law and the registration lists are published.
The caveat is that this structure is specific to one jurisdiction and does not describe the position elsewhere.
This structure is jurisdiction-specific. It does not describe your country unless it does.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant point is that the heavier-obligation category is inspected against manufacturing standards and the lighter one is not.
The practical consequences: an outsourcing facility can supply office stock and distribute at volume; a patient-specific compounder cannot do either without stepping outside its category.
Specifically, outsourcing facilities may produce without a patient-specific prescription, register federally, are inspected on a risk-based schedule and are subject to current good manufacturing practice.
Adverse event reporting obligations attach to registered outsourcing facilities and are the basis for what public information exists.
Neither category yields an approved product, and the distinction is often blurred in marketing.
Neither category is an approved product. That is unchanged by registration.
Start with which category a facility is registered under, because it is a matter of public record and it tells you what it can legally do.
Adverse event reporting obligations attach to the outsourcing category and not to the patient-specific one, which is a real difference in the information that exists about what a facility produces.
A facility that will not say which category it operates under has told you something, and the registration lists will tell you the rest.
The category tells you which standards apply, not how good the preparation is.
The honest answer is that the category tells you about obligations rather than about the quality of any particular preparation.
Patient-specific compounding requires a prescription for a named individual, is regulated primarily at state level, and is not subject to current good manufacturing practice requirements.
A registration category describes obligations, not the quality of any particular preparation.
Inspection findings are public for registered facilities. Read them.
edited 1 Apr 2026 by Dr_Nadia_Farsi — removed a claim I could not source
The short version: patient-specific compounding under one framework, office-stock production under the other, with much heavier obligations on the second.
Neither category produces an approved product. Both operate outside the marketing-authorisation framework, and the difference is in the manufacturing standards applied, not in approval status.
Check the registration list. It takes a minute and it is the one verifiable claim here.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.